Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir in Sepsis-Associated Acute Respiratory Failure
NCT04706507Phase 3Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of ganciclovir in acute respiratory failure (ARF), sepsis, sponsored by Fred Hutchinson Cancer Center. Started Jun 2021; status: terminated.
02
Drugs
ganciclovir
03
Conditions
acute respiratory failure (ARF)sepsis
Beyond the preview
Go deeper on NCT04706507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706507.